Application of protein muc13 in preparation of reagents for diagnosing intrahepatic cholangiocarcinoma

A technology for intrahepatic cholangiocarcinoma and protein, applied in the field of medicine, to achieve highly specific effects

Active Publication Date: 2021-07-27
HARBIN MEDICAL UNIVERSITY
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there is no report on the use of MUC13 protein as a biomarker for intrahepatic cholangiocarcinoma

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of protein muc13 in preparation of reagents for diagnosing intrahepatic cholangiocarcinoma
  • Application of protein muc13 in preparation of reagents for diagnosing intrahepatic cholangiocarcinoma
  • Application of protein muc13 in preparation of reagents for diagnosing intrahepatic cholangiocarcinoma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0046] Example 1 Determination of Candidate Serum Biomarkers

[0047] The inventors of the present invention used the advantages of high-throughput and rapid analysis of human proteome chips to analyze 60 serum samples related to intrahepatic cholangiocarcinoma (30 serum samples from patients with intrahepatic cholangiocarcinoma and 30 serum samples from healthy people). Comparing the difference between samples from patients with intrahepatic cholangiocarcinoma and healthy people, it was found that the expression level of MUC13 protein in patients with intrahepatic cholangiocarcinoma was significantly higher than that in healthy people, suggesting that MUC13 protein can be used as a candidate serum for intrahepatic cholangiocarcinoma Biomarkers for early diagnosis and effective treatment of intrahepatic cholangiocarcinoma.

Embodiment 2

[0048] Example 2 Application of MUC13 Protein in Diagnosis of Intrahepatic Cholangiocarcinoma

[0049] 1. Expression, purification and identification of MUC13:

[0050] The protein MUC13 is obtained from genetically engineered Saccharomyces cerevisiae, induced overexpression by galactose, separated and purified by agarose affinity medium (glutathione), and the results of silver staining quantification and Western-Blotting identification were respectively Such as figure 1 shown.

[0051] 2. Preparation of serum samples:

[0052] After all the specimens were left at room temperature for 2 hours, centrifuge at 2000g for about 5 minutes, and the supernatant was taken for immediate detection; or aliquoted, and the specimens were stored at -20°C or -80°C, but repeated freezing and thawing should be avoided. Thawed samples should be centrifuged again prior to testing. The tested samples cannot contain NaN 3 , because NaN 3 Inhibits horseradish peroxidase (HRP) activity.

[005...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Sensitivityaaaaaaaaaa
Login to view more

Abstract

The invention discloses the application of protein MUC13 in the preparation of reagents for diagnosing intrahepatic cholangiocarcinoma. The present invention utilizes the advantages of high-throughput and rapid analysis of the human proteome chip to analyze the relevant serum of patients with intrahepatic cholangiocarcinoma, compare the differences between the samples of intrahepatic cholangiocarcinoma patients and healthy people in a short period of time, and find that the MUC13 protein The expression level of MUC13 in patients with intrahepatic cholangiocarcinoma was significantly higher than that in healthy people, suggesting that MUC13 protein can be used as a candidate serum biomarker for intrahepatic cholangiocarcinoma for early diagnosis and effective treatment of intrahepatic cholangiocarcinoma. Tests have proved that the serum marker MUC13 provided by the present invention has a specificity of 90%, a sensitivity of 91.67%, and has the characteristics of high specificity and high sensitivity. Further, the present invention also provides a sensitive, safe, reliable, and easy-to-operate commercial kit, which can be used to qualitatively measure the level of anti-MUC13 IgG antibody in human serum, which is helpful for the early diagnosis of intrahepatic cholangiocarcinoma.

Description

technical field [0001] The invention relates to a new serum biomarker for early diagnosis of intrahepatic cholangiocarcinoma, and also relates to a kit containing the serum biomarker. The invention belongs to the technical field of medicine. Background technique [0002] Intrahepatic cholangiocarcinoma (iCCA) is a highly malignant tumor originating from the intrahepatic biliary epithelium, ranking second among liver malignancies. Epidemiological studies suggest that its morbidity and mortality are on the rise worldwide in recent years. Due to the insidious onset, lack of effective tumor markers, and the characteristics of early metastasis, most of the diagnosed patients are in the middle and late stage, and lose the chance of radical surgical resection or liver transplantation. At the same time, intrahepatic cholangiocarcinoma is not sensitive to traditional radiotherapy and chemotherapy, and there is a lack of effective molecular targeted drugs, which puts patients in the...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): G01N33/574
CPCG01N33/57438
Inventor 裴铁民肖鹏
Owner HARBIN MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap